Condensed Consolidated Statements of Mezzanine and Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Total	Conversion Of Convertible Preferred Stock	Series C Preferred Stock	Series C Preferred Stock Private Placement	Series C Preferred Stock AlmataBio Transaction	Series D Preferred Stock	Series D Preferred Stock Private Placement	Series E Preferred Stock	Series E Preferred Stock Private Placement	Common stock	Common stock Conversion Of Convertible Preferred Stock	Series C preferred stock Series C Preferred Stock	Additional Paid-in Capital	Additional Paid-in Capital Conversion Of Convertible Preferred Stock	Accumulated other comprehensive income	Accumulated deficit
Balance at the beginning (in shares) at Dec. 31, 2023	0
Balance at the beginning at Dec. 31, 2023	$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of stock (in shares)				19,946	2,412		1		1
Issuance of Series C Preferred Stock pursuant to AlmataBio Transaction					$ 11,457
Retirement of Series C Preferred Stock in exchange for issuance of common stock (in shares)	(8,648)
Retirement of Series C Preferred Stock in exchange for issuance of common stock	$ (9,799)
Balance at the end (in shares) at Sep. 30, 2024	13,712
Balance at the end at Sep. 30, 2024	$ 1,658
Balance at the beginning (in shares) at Dec. 31, 2023										801,746
Balance at the beginning at Dec. 31, 2023	7,304									$ 1		$ 0	$ 342,437			$ (335,134)
Balance at the beginning (in shares) at Dec. 31, 2023												0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in exchange for retirement of Series C Preferred Stock (in shares)										171,605	8,648,244
Issuance of common stock in exchange for retirement of Series C Preferred Sock		$ 9,799									$ 9			$ 9,790
Impact of reverse split fractional share round-up (in shares)										60,779
Issuance of common stock pursuant	815												815
Stock-based compensation	2,948												2,948
Net (loss) income	210															210
Balance at the end (in shares) at Sep. 30, 2024										9,682,374
Balance at the end at Sep. 30, 2024	$ 21,076									$ 10		$ 0	355,990			(334,924)
Balance at the end (in shares) at Sep. 30, 2024												0
Balance at the beginning (in shares) at Jun. 30, 2024	22,360
Balance at the beginning at Jun. 30, 2024	$ 11,457
Increase (Decrease) in Temporary Equity [Roll Forward]
Retirement of Series C Preferred Stock in exchange for issuance of common stock (in shares)	(8,648)
Retirement of Series C Preferred Stock in exchange for issuance of common stock	$ (9,799)
Balance at the end (in shares) at Sep. 30, 2024	13,712
Balance at the end at Sep. 30, 2024	$ 1,658
Balance at the beginning (in shares) at Jun. 30, 2024										1,034,130
Balance at the beginning at Jun. 30, 2024	(13,608)									$ 1		$ 0	344,352			(357,961)
Balance at the beginning (in shares) at Jun. 30, 2024												0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in exchange for retirement of Series C Preferred Stock (in shares)											8,648,244
Issuance of common stock in exchange for retirement of Series C Preferred Sock		$ 9,799									$ 9			$ 9,790
Stock-based compensation	1,848												1,848
Net (loss) income	23,037															23,037
Balance at the end (in shares) at Sep. 30, 2024										9,682,374
Balance at the end at Sep. 30, 2024	$ 21,076									$ 10		$ 0	355,990			(334,924)
Balance at the end (in shares) at Sep. 30, 2024												0
Balance at the end (in shares) at Dec. 31, 2024	2					1		1
Balance at the end at Dec. 31, 2024	$ 0					$ 0		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock pursuant (in shares)			11,186.267							781,259
Balance at the end (in shares) at Dec. 31, 2024	10,471,934									10,471,934
Balance at the end at Dec. 31, 2024	$ 133,032									$ 10		$ 0	503,285		$ 0	(370,263)
Balance at the end (in shares) at Dec. 31, 2024			24,896									24,896
Balance at the end (in shares) at Sep. 30, 2025	2					1		1
Balance at the end at Sep. 30, 2025	$ 0					$ 0		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in exchange for retirement of Series C Preferred Stock (in shares)										5,531,946		(5,532)
Issuance of common stock in exchange for retirement of Series C Preferred Sock	0									$ 6			(6)
Issuance of common stock pursuant (in shares)										1,658,333
Issuance of common stock pursuant	14,370									$ 2			14,368
Vesting of Restricted Stock Units net of shares withheld for taxes (in shares)										155,686
Vesting of Restricted Stock Units net of shares withheld for taxes	(510)												(510)
Shares purchased through employee stock purchase plan (in shares)										9,736
Issuance of common stock in exchange for retirement of Series C Preferred Stock	40												40
Unrealized gain on investments, net	41														41
Stock-based compensation	9,113												9,113
Net (loss) income	$ (64,539)															(64,539)
Balance at the end (in shares) at Sep. 30, 2025	17,827,635									17,827,635
Balance at the end at Sep. 30, 2025	$ 91,547									$ 18		$ 0	526,290		41	(434,802)
Balance at the end (in shares) at Sep. 30, 2025			19,364									19,364
Balance at the beginning (in shares) at Jun. 30, 2025	2
Balance at the beginning at Jun. 30, 2025	$ 0
Balance at the end (in shares) at Sep. 30, 2025	2					1		1
Balance at the end at Sep. 30, 2025	$ 0					$ 0		$ 0
Balance at the beginning (in shares) at Jun. 30, 2025										10,837,356
Balance at the beginning at Jun. 30, 2025	104,574									$ 11		$ 0	508,774		(34)	(404,177)
Balance at the beginning (in shares) at Jun. 30, 2025												24,696
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in exchange for retirement of Series C Preferred Stock (in shares)										5,331,946		(5,332)
Issuance of common stock in exchange for retirement of Series C Preferred Sock	0									$ 5			(5)
Issuance of common stock pursuant (in shares)										1,658,333
Issuance of common stock pursuant	14,370									$ 2			14,368
Unrealized gain on investments, net	75														75
Stock-based compensation	3,153												3,153
Net (loss) income	$ (30,625)															(30,625)
Balance at the end (in shares) at Sep. 30, 2025	17,827,635									17,827,635
Balance at the end at Sep. 30, 2025	$ 91,547									$ 18		$ 0	$ 526,290		$ 41	$ (434,802)
Balance at the end (in shares) at Sep. 30, 2025			19,364									19,364

Avalo Therapeutics, Inc. 10-Q